selected publications
-
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
Journal for immunotherapy of cancer.
2020
Academic Article
GET IT
Times cited: 169 -
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Annals of oncology : official journal of the European Society for Medical Oncology.
2019
Academic Article
GET IT
Times cited: 48 -
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2019
Academic Article
GET IT
Times cited: 15 -
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
JAMA oncology.
2018
Academic Article
GET IT
Times cited: 376 -
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Journal for immunotherapy of cancer.
2018
Academic Article
GET IT
Times cited: 298 -
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
The Lancet. Oncology.
2016
Academic Article
GET IT
Times cited: 1118 -
Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
2016
Information Resource
GET IT
Times cited: 10 -
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas.
European journal of cancer.
2015
Academic Article
GET IT
Times cited: 90 -
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.
Sarcoma.
2015
Academic Article
GET IT
Times cited: 54 -
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
The Lancet. Oncology.
2015
Academic Article
GET IT
Times cited: 1712 -
Soft tissue tumors of the trunk: management of local disease in the breast and chest and abdominal walls.
Journal of surgical oncology.
2014
Review
GET IT
Times cited: 15 -
Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.
The American journal of surgical pathology.
2014
Academic Article
GET IT
Times cited: 155 -
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
Clinical lung cancer.
2014
Academic Article
GET IT
Times cited: 36 -
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2012
Academic Article
GET IT
Times cited: 128 -
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2012
Academic Article
GET IT
Times cited: 586 -
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
Cancer.
2012
Academic Article
GET IT
Times cited: 54 -
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2011
Academic Article
GET IT
Times cited: 274 -
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2011
Academic Article
GET IT
Times cited: 118 -
Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.
The Journal of thoracic and cardiovascular surgery.
2010
Academic Article
GET IT
Times cited: 33 -
The molecular pathogenesis of small cell lung cancer.
Cancer biology & therapy.
2010
Information Resource
GET IT
Times cited: 37 -
Hepatitis C virus infection does not preclude standard breast cancer-directed therapy.
Clinical breast cancer.
2009
Academic Article
GET IT
Times cited: 5